Inducing angiogenesis and endothelial cell permeability
|
Enhancement of angiogenesis
|
miR-9-5p
|
SOCS5
|
Melanoma cells
|
Endothelial cells
|
[24]
|
Enhancement of angiogenesis
|
miR-210-3p
|
EFNA3
|
Lung cancer cells
|
Endothelial cells
|
[25, 26]
|
Enhancement of angiogenesis and vascular permeability
|
miR-23a-3p
|
PHD 1 and 2, ZO-1
|
Lung cancer cells
|
Endothellial cells
|
[27]
|
Destruction of BBB
|
miR-105-5p
|
ZO-1
|
Breast cancer cells
|
Endothelial cells (distant site)
|
[32]
|
Destruction of BBB
|
miR-181c-5p
|
PDPK1
|
Breast cancer cells
|
Endothelial cells (distant site)
|
[33]
|
Crosstalk between cancer cells and stromal fibroblasts
|
Induction of CAFs
|
miR-155-5p
|
TP53INP1
|
Pancreastic cancer cells
|
Fibroblasts
|
[40]
|
Suppression of apoptosis and confering chemoresistance
|
miR-21-5p
|
AFAP1
|
CAFs and CAAs
|
Breast cancer cells
|
[41]
|
Stemness and EMT
|
miR-21-5p, miR-378e and miR-143-3p
|
Not mentioned
|
CAFs
|
Breast cancer cells
|
[42]
|
Induction of CAFs
|
miR-9-5p
|
Not mentioned
|
Breast cancer cells
|
Fibroblasts
|
[43]
|
Development of premetastatic niche
|
miR-494 and miR-542-3p
|
CDH17
|
Metastatic rat pancreatic adenocarcinoma
|
Lymph node stromal cells and lung fibroblasts (distant site)
|
[44]
|
Development of premetastatic niche
|
miR-122-5p
|
PKM2, CS
|
Breast cancer cells
|
Astrocytes and lung fibroblasts (distant site)
|
[45]
|
Modulation of immune system
|
Induction of TAMs
|
miR-21-5p and miR-29a-3p
|
Directly bind to TLR family (murine TLR7 and human TRL8)
|
Lung cancer cells
|
Murine macrophages
|
[53]
|
Induction of TAMs
|
miR-222-3p
|
SOCS3
|
EOC cells
|
Monocytes
|
[54]
|
Regulation of cancer cell proliferation and drug resistance
|
Supression of cancer cell proliferation (competition during cancer initiation)
|
miR-143-3p
|
KRAS and ERK5
|
Normal prostate epithelial cells
|
Prostate cancer cells
|
[16]
|
Promoting MET
|
miR-200 family
|
ZEB2, SEC23A
|
Highly metastatic lung cancer cells
|
Weakly metastatic lung cancer cells
|
[61]
|
Promoting invasiveness
|
miR-10b-5p
|
HOXD10
|
Metastatic breast cancer cells
|
Non-malignant breast epithelial cells
|
[62]
|
Adriamycin and docetaxel resistance
|
miR-30a-5p, miR-100-5p and miR-222-3p
|
PTEN (miR-222)
|
Drug resistant breast cancer cells
|
Drug sensitive breast cancer cells
|
[64]
|
Gemcitabine resitance
|
miR-222-3p
|
SOCS3
|
Drug resistant NSCLC cells
|
Drug sensitive NSCLC cells
|
[65]
|
Activating monocytes
|
miR-21-5p
|
Directly bind to TRL8
|
Neuroblastoma cells
|
Human monocytes
|
[66]
|
Cisplatin resistance
|
miR-155-5p
|
TERF1
|
Activated monocytes
|
Neuroblastoma cells
|
[66]
|
Induction of dormant state (long-term recurrecnce)
|
miR-23b-3p
|
MARCKS
|
BM–MSCs
|
Breast cancer cells
|
[68]
|